Unfortunately, I don't do their marketing so unable to answer your question. One thing I can give my opinion on is that the IP of the company is rock solid and will be a major player in the immunology field. It's a shame Covid got in the way, other wise we would all be singing a different tune.
Will they have another go at Covax19? Novax $12 Billion USD Cap, page-80
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
